The Legacy of a Legend…Farewell, Mr. Palmer

Screen Shot 2016-10-18 at 1.09.50 PM.png

image courtesy of

Recently, golf legend, Arnold Palmer passed away. We’re all aware of the legacy of golf achievements the man left. Over 9o championships, in addition to 18 wins in foreign championships and 12 wins on the senior tour he was not only a force on the golf course, but in the community of cancer research and treatment.

This is a less well-known part of Arnold’s history, as he was more concerned with moving the cause forward than personal notority. At age 67 in 1997, Arnold had a PSA screening test for prostate cancer. His PSA had been rising for 2-3 years and had resulted in 2 prior normal prostate biopsies. But this time, his third biopsy showed him to have prostate cancer. He went to Mayo clinic where the doctors discussed the treatment options. Wanting the highest chance for cure, Arnold opted for surgery to remove his prostate. The findings showed enough risk for possible recurrence that he then received 7 weeks of radiation therapy. Remarkably, only 6 weeks later, after physical therapy, Arnold was back on the golf course competing in tournaments.

He won the admiration of his fans (known as Arnie’s Army) and all Americans by becoming a lifelong spokesperson for prostate cancer control. He advocated prostate cancer screening with PSA. Regarding screening, and in keeping with current recommendations, he felt that men’s lives would be better if they just talked to their doctor about it. “That’s health and living”, he said, and felt that being healthy is the “good life”.

Arnold also formed the Arnold Palmer Prostate Center in Palm Springs at the Eisenhower Lucy Curie Cancer Center, and then supported the Arnold Palmer Pavilion at U. Pittsburgh Medical Center and Latrobe Area Hospital. Because of his advocacy, many more men have been cured of prostate cancer and are survivors.

Funny Man Ben Stiller: Prostate cancer test ‘saved my life’


Actor Ben Stiller revealed on Tuesday he was diagnosed with prostate cancer in 2014. The tumor was surgically removed three months later, in September 2014, and Stiller has been cancer-free since.

Stiller shared the news on Howard Stern’s Sirius XM radio show, and in an essay posted online.

According to Stiller, it was the prostate-specific antigen test, a blood test known as the PSA, that saved his life. He was tested and treated in his 40s.

To Read More at Click Here!   Be sure to check out the infographics below to see what risk factors affect you!

IPCF-2016-Prostate-Cancer-RiskFactors-Infographic- FULL.png

The Doctor’s Doctor!


Our Founder Dr. Vipul Patel was recently featured in the May 2016 issue of Vero Beach Magazine.  To read and excerpt of the article visit here.

To download a PDF scan of the full article visit this link!


IPCF sponsors the Audi Quattro Cup with much success!


We are always looking for solid partnerships to help spread #prostatecancerawareness. Recently, IPCF partnered with Audi to sponsor their local Audi Quattro Cup, giving the winning twosome a chance to advance to the U.S. Final held in Charleston, South Carolina. There was a great response with many attendees, including IPCF Board Member Wilson Dondo, as well as Prostate Cancer Survivor and former American football player Louis Leo “Lou” Holtz is a former American football player.

Founder, Dr. Vipul Patel spoke about #prostatecancerawareness and the importance of prostate cancer screening and awareness. And all proceeds of the event were donated by Audi to the International Prostate Cancer Foundation.

AAB_7680 AAB_7645AAB_7663 AAB_8057 AAB_8033 AAB_8030 AAB_8026 AAB_8017 AAB_8001 AAB_7957 AAB_7942 AAB_7919 AAB_7913

Get to know IPCF Board Member, Oscar Robertson!

Screen Shot 2015-08-11 at 11.10.31 AM

Here at the International Prostate Cancer Foundation we are lucky to have the support of our many esteemed board members.They donate their time, expertise and financial support to continuing our efforts to fight prostate cancer and it’s effects.

Recently, board member Oscar Robertson, was featured in The Wall Street Journal.  You can read more about Oscar and his road to success here! Congratulations Oscar, you have shown us all what it’s like to succeed while overcoming the challenges life throws at us.

Founder’s Study on Improving Outcomes


Our mission here at IPCF, among others, is to participate in continuing research regarding Prostate Cancer Treatments. Founder, Dr. Vipul R. Patel recently published a study on AminoFix that was picked up by OncLive. 

Read a brief summary of the study below, or click here to read the full article.

Using an allograft made up of dehydrated human amnion/chorion membrane (dHACM) wrapped around the neurovascular bundle (NVB) during nerve-sparing robot-assisted radical prostatectomy (RARP) improved continence and potency postsurgery, according to results of a small study conducted by Vipul R. Patel, MD, professor of urology, University of Central Florida College of Medicine and medical director, Global Robotics Institute at Florida Hospital Celebration Health. Findings were published online in European Urology.

– See more at:–Robot-Assisted-Radical-Prostatectomy#sthash.eEQtTeoB.dpuf

Prostate Cancer Research is the focus of the Journal of Molecular Diagnostic in November


We are always happy to see Prostate Cancer Research make it into the public forum. And this month we are proud to say our board member Ranjan J. Perera, is leading groundbreaking research in Putative Biomarkers for Prostate Cancer Detection. IPCF is proud to say, last year we awarded a grant to the Sanford-Burnham Institute for Medical Research, which resulted in this landmark research for prostate cancer biomarkers.

Prostate cancer is the leading cause of cancer and the second leading cause of cancer related death in males. While much work has been done in the realm of prostate cancer diagnosis there is still no agreement on a single diagnostic marker to be used for definitive diagnosis. Markers that are frequently used as diagnostic tools of prostate cancer include PSA and PCA3. Both markers however have limitations. PSA may lead to certain confusing situations when some other diseases such as inflammation (prostatitis) or benign prostate hyperplasia can provoke the same degree of PSA changes.  PCA3 as a urine marker was recently introduced in wide clinical practice. Although it is proven to exclude prostate cancer, the overall value of this test is limited to predict aggressive nature of the disease. This leaves room for improvement in the detection of prostate cancer.

In this collaborative study done at the Sanford-Burnham Medical Research Institute and Global Robotics Institute six main genes are searched in as a potential diagnostic tools to improve the diagnosis and risk stratification of prostate cancer. These are small molecules of RNA (ribonucleotide acids) that can play a crucial role in cancer development and progression. These molecules can be found in prostate tissue as well as in urine or blood.

The study consisted of 3 parts. The first one compared the level of this molecular gene information between healthy versus cancerous prostate tissue from laboratory-produced prostate cancer cells. The second analysis included a comparative measurement of these molecules from biopsy tissue of patients with and without prostate cancer. The third one performed an analysis of urine samples for these molecules between normal and cancerous patients. What was found was that these RNA structures were found in significantly increased levels in all cancer groups in comparison to the non-cancerous groups.

The initial results of this study demonstrated the promising value of newly discovered gene molecules as additional diagnostic tools that can be detected in tissue, blood and urine.  We can combine the use of these markers with additional parameters such as PSA and PCA3 to increase the accuracy of diagnosing prostate cancer. Additional studies may be carried out to further evaluate the utility of these markers.

To download the full article click here, and download from the right hand side of the page.

On the Lighter Side. . .

image purchased at

We all know that Dogs are amazing creatures, not only are they man’s loyal best friend, they often aid us by performing jobs to help better society. Drugs, explosives, and blood, are just a few of the things dogs have been trained to sense. They have also proved successful in tracking other animals, missing persons and suspects to aid police. There is even evidence to suggest those powerful sniffers can aid in early detection of cancer!

Published studies have shown that dogs can detect early stage cancer with 88% specificity, and 99% sensitivity. You may have even seen some cases in the media where a woman’s pet alerted them to breast cancer growing within her.  There is no denying a dog’s extraordinary sense of smell. While we have around 5 million olfactory cells in our noses – receptors that detect different odors – dogs have approximately 200 million. It is dogs’ acute ability to trace scents that has made them so attractive to the medical world. More recently, those cuddly canines appeared in the news again for the detection of prostate cancer!

  • Italian researchers say they’ve trained two female German shepherd dogs to sniff out prostate cancer and the canines have greater than 90% accuracy.
  • The research team from the Humanitas Clinical and Research Center in Milan, Italy collected urine samples from 362 men diagnosed with prostate cancer at various stages of the disease. They also collected urine samples from 418 men and 122 women who were either healthy, had a different kind of cancer or who had a different health condition.
  • They then trained Zoe and Liu, three-year-old bomb detection dogs who worked with the Italian armed forces, to detect specific volatile organic compounds in urine associated with prostate cancer.
  • After the dogs were retrained, they were tested using batches of six urine samples from the men with prostate cancer, positioned at random among the non-prostate cancer urine samples.
  • (bulleted information from

This is an interesting development and we are excited to follow it and watch it develop. So remember, your dog isn’t just a wonderful companion in your life, he’s a hero that could save it!  For more information on dogs detecting cancer, please visit some of the resources below.

Showing Gratitude to IPCF Board Member, Wilson Dondo!

Here at the International Prostate Cancer Foundation we are lucky to have the support of our many esteemed board members.
They donate their time, expertise and financial support to continuing our efforts to fight prostate cancer and it’s effects.

Recently, board member Wilson Dondo, has contributed his time and efforts to help secure a financial gift from a prostate cancer survivor. Donations like this are important in our continued research and developments of treatments to continue to make an impact in the field of prostate cancer. And having wonderful board members, like Mr. Dondo fighting in our corner, contributes to continued breakthroughs.

Wilson Dondo

Mr. Dondo joined our board in early 2014, he holds a Masters Degree in Marketing as well as a Business Degree. He is a member of the International Prostate Cancer Foundation board and co- founder of VMD Group. He continues to lend his efforts to fundraising for IPCF.

We are proud to have someone as a member of our board who gives back to our community so generously.

If you would like to donate to the International Prostate Cancer Foundation, please contact us at or donate directly here.

8,000 Lives and Going Strong!

Congratulations to our Founder, Dr. Vipul Patel. He and his team at the Global Robotics Institute completed 8,000 surgeries today! Visit us at @endprostatecancer on twitter and wish him congratulations!

8K Congrats